$MRNA.US Moderna Just Lit Up the Biotech Sector 🚀🚀🚀
Moderna shares exploded nearly 90% after the company reported encouraging late-stage trial results for a personalized mRNA cancer vaccine developed with Merck. The treatment significantly reduced melanoma recurrence compared with the standard treatment in the study.$MRK.US
The move was big enough to lift other biotech names too, with Merck, Novavax and BioNTech also gaining. More importantly, the data gives investors another reason to watch personalized cancer treatments as mRNA technology expands beyond infectious diseases. $NVAX.US
This is the kind of clinical result that can completely reset expectations for a biotech company. 🔬
Moderna shares exploded nearly 90% after the company reported encouraging late-stage trial results for a personalized mRNA cancer vaccine developed with Merck. The treatment significantly reduced melanoma recurrence compared with the standard treatment in the study.$MRK.US
The move was big enough to lift other biotech names too, with Merck, Novavax and BioNTech also gaining. More importantly, the data gives investors another reason to watch personalized cancer treatments as mRNA technology expands beyond infectious diseases. $NVAX.US
This is the kind of clinical result that can completely reset expectations for a biotech company. 🔬